Dr. Uzzo on Biomarker Development for RCC

Robert G. Uzzo, MD
Published: Friday, Nov 10, 2017



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

There are currently no biomarkers for patients with RCC, states Uzzo. Researchers are investigating immunohistochemical stains as a potential biomarker, but further research is needed.

According to Uzzo, the most effective biomarker will be easily collected and will have a high sensitivity and specificity.



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

There are currently no biomarkers for patients with RCC, states Uzzo. Researchers are investigating immunohistochemical stains as a potential biomarker, but further research is needed.

According to Uzzo, the most effective biomarker will be easily collected and will have a high sensitivity and specificity.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x